Pharma Focus Europe
ThermoFisher Scientific - Custom and Bulks

ReAlta Life Sciences Commences Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease with First Patient Dosing

Thursday, February 22, 2024

ReAlta Life Sciences, Inc., a biotech company specializing in mid-stage clinical research, has initiated enrollment for a Phase 2 clinical trial for RLS-0071. This investigational drug, developed from ReAlta’s EPICC peptide platform, aims to address acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) in hospitalized patients. RLS-0071, the company’s primary dual-targeting peptide, inhibits both complement and neutrophil-associated inflammation. It is currently being explored for treating conditions like hypoxic ischemic encephalopathy and acute graft-versus-host disease.

Dr. Kenji Cunnion, ReAlta's Chief Medical Officer, expressed optimism about RLS-0071's unique mechanism-of-action, which targets complement activation and neutrophil effectors. He highlighted the urgent need for effective AE-COPD treatments due to the limited options currently available.

ReAlta's CEO, Dr. Ulrich Thienel, emphasized the significance of this milestone, with two Phase 2 trials now underway. He underscored the substantial unmet need in AE-COPD treatment and the potential of RLS-0071 to address it effectively.

The Phase 2 trial is a randomized, double-blind, placebo-controlled study assessing RLS-0071's safety, pharmacokinetics, and pharmacokinetic-pharmacodynamic relationships in AE-COPD patients. Approximately 24 hospitalized patients will receive RLS-0071 or a placebo alongside standard care for up to five days. The primary endpoint is safety, with secondary endpoints including inflammation biomarkers, physiological responses, and clinical progression and resolution.

AE-COPD involves sudden exacerbations of respiratory symptoms triggered by lung infections or environmental irritants. These exacerbations can lead to hospitalization, irreversible lung damage, and death.



Get instant
access to our latest e-book
patheon - Mastering API production at every scaleLab Indonesia 20247th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing PharmaWorld Vaccine Congress Europe 2024